FluGen has been awarded an $11.4 million grant from the United States Department of Defense to conduct a safety and immunogenicity study of the influenza vaccine (M2SR, the company announced…

FluGen announced today it has dosed its first patients in a clinical trial of a novel investigational influenza vaccine called M2SR against multi-season mismatched strains, in Belgium. “If successful, the results from…

FluGen will evaluate its influenza vaccine in a trial of 100 people later this spring, the company announced recently. “Our vaccine contains a live virus that infects you but cannot make…

FluGen announced today it has begun a Phase I clinical trial of its universal influenza vaccine called RedeeFlu. “The initiation of this first-in-man study is an important milestone achieved through…